Cure8 research brief
Pregnancy outcomes in people with IBD are linked to disease activity and treatment. This study compares outcomes across women who continued, stopped, never used, or started biologics during pregnancy, which can inform decisions about biologic management in pregnancy.
Pregnant people with IBD or planning pregnancy, their partners/caregivers, IBD clinicians, and obstetricians.
The report supports the idea that ongoing disease control going into and during pregnancy matters. Women who stopped biologics before or during pregnancy (discontinuers) experienced more third‑trimester disease activity and numerically higher rates of C‑section and preterm birth than those who continued therapy.
Small-for-gestational-age was numerically higher among continuers, a finding the authors say needs more study. Initiators were few and had the worst outcomes, suggesting that starting biologics during pregnancy may reflect poorly controlled disease rather than a treatment effect.
How to use this: This is real-world, single‑center retrospective data that adds to evidence considered by recent consensus recommendations to continue biologics during pregnancy, but it cannot prove causation. Decisions about stopping or continuing biologics in pregnancy should remain individualized and discussed with your IBD clinician and obstetric team.
This is a retrospective single‑center study with small numbers in some groups (especially initiators). The abstract-level data report numerical differences without extensive confounder adjustment; larger adjusted studies are needed. The article is an abstract-based summary from a peer-reviewed journal.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD may face higher-than-expected rates of hypertensive disorders in pregnancy; identifying predictors could help target monitoring and preventive strategies. The study suggests prior HDP and gestational...
Pregnant people with IBD or other autoimmune diseases often face tough choices about continuing biologics or JAK inhibitors. CARE-HP aims to produce broader, disease-specific evidence to help patients and clinicians...
People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...
